Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

OvaRex (oregovomab) / CanariaBio

QPT-ORE-004, NCT05335993: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Active, not recruiting

Oregovomab, MAb-B43.13, Monoclonal antibody B43.13, Niraparib, Zejula

CanariaBio Inc., Veristat, LLC

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary

03/24

12/24

OPERA, NCT05407584: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting

RoW

Orevogomab+PLD, Orevogomab+Paclitaxel

Yonsei University, CanariaBio Inc.

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

05/24

11/24

QPT-ORE-006, NCT05605535: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

Recruiting

RoW

Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo

CanariaBio Inc., Raptim Research Pvt. Ltd

Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma, Ovarian Serous Adenocarcinoma

09/24

05/26

NCT04938583: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Recruiting

1b/2

RoW

Oregovomab, MAb-B43.13, Bevacizumab, Avastin, Paclitaxel, Taxol, Paxcel, Padexol, Carboplatin, Neoplatin

CanariaBio Inc., Korean Cancer Study Group

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV

04/24

12/25

ORION-02, NCT04620954: Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Recruiting

1/2

RoW

Oregovomab, Nivolumab, Chemotherapy

National Cancer Centre, Singapore, OncoQuest Pharma USA Inc., Bristol-Myers Squibb

Epithelial Ovarian Cancer

07/22



	Diseases Companies Products Productz Mechanisms of Action Sites